Hydron;1-(5-iodonaphthalen-1-yl)sulfonyl-1,4-diazepane;chloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: Hydron;1-(5-iodonaphthalen-1-yl)sulfonyl-1,4-diazepane;chloride
• 化学式: C15H18ClIN2O2S
• mdl: MFCD00065524
• 分子量: 452.7
• InChiKey: KDDALCDYHZIZMH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.47
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  57.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  高哌嗪 、 5-碘萘-1-磺酰氯 生成 Hydron;1-(5-iodonaphthalen-1-yl)sulfonyl-1,4-diazepane;chloride
  参考文献：
  名称：

  XIDAKA, XIROESI;TANAKA, TOSIO;ITO, YASUO;KATO, XIDEHO;EHTTYU, EHJITI;OGAV+

  摘要：

  DOI：

文献信息

• GUT FLORA-DERIVED EXTRACELLULAR VESICLES, AND METHOD FOR SEARCHING FOR A DISEASE MODEL, VACCINE, AND CANDIDATE DRUG AND FOR DIAGNOSIS USING SAME
  申请人：Aeon Medix Inc.

  公开号：EP2494865A2

  公开（公告）日：2012-09-05

  The present invention relates to a composition including gut flora-derived extracellular vesicles, and to an animal disease model using same. In addition, the present invention relates to a method for using the gut flora-derived extracellular vesicles to efficiently search for a candidate drug which may prevent or treat diseases that occur due to gut flora-derived extracellular vesicles, and to a vaccine which can efficiently prevent or treat infections caused by gut flora or diseases that occur due to gut flora-derived extracellular vesicles. Further, the development of diagnostic technology to discover, using the gut flora-derived extracellular vesicles of the present invention, the etiology of diseases that occur due to gut flora-derived extracellular vesicles, can be achieved.

  本发明涉及一种包括源自肠道菌群的细胞外囊泡的组合物，以及使用该组合物的动物疾病模型。此外，本发明还涉及一种使用肠道菌群衍生的胞外囊泡来有效寻找候选药物的方法，该候选药物可预防或治疗因肠道菌群衍生的胞外囊泡而发生的疾病；本发明还涉及一种疫苗，该疫苗可有效预防或治疗由肠道菌群引起的感染或因肠道菌群衍生的胞外囊泡而发生的疾病。此外，还可以开发诊断技术，利用本发明的肠道菌群源性细胞外囊泡发现因肠道菌群源性细胞外囊泡引起的疾病的病因。
• Derivation of hepatic stem cells and mature liver cell types and uses thereof
  申请人：AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH

  公开号：US10683484B2

  公开（公告）日：2020-06-16

  This application describes liver stem cells (LSC), and differentiated hepatocytes, cholangiocytes, and 3D cellular structures derived therefrom. Methods for producing LSC and mature, differentiated hepatocytes and cholangiocytes in culture are provided. Also provided are cell culture systems and cell culture media for producing a homogenous population of liver stem cells that remain in an undifferentiated state over multiple passages in culture. The LSC and methods are useful for producing homogenous populations of hepatocytes and cholangiocytes for downstream applications. The LSC can be transplanted into subjects to treat liver diseases.

  本申请介绍了肝干细胞（LSC）、分化的肝细胞、胆管细胞以及由此衍生的三维细胞结构。本申请提供了在培养过程中产生 LSC 以及成熟、分化的肝细胞和胆管细胞的方法。此外，还提供了细胞培养系统和细胞培养基，用于产生在培养过程中多次传代保持未分化状态的同源肝干细胞群。这种肝干细胞和方法可用于生产下游应用所需的同源肝细胞和胆管细胞。肝干细胞可移植到受试者体内治疗肝脏疾病。
• UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY AGENTS THAT DISRUPT ACTIN CYTOSKELETAL ORGANIZATION
  申请人：——

  公开号：US20020082281A1

  公开（公告）日：2002-06-27

  A use for agents that disrupt actin cytoskeletal organization is provided. In the instant invention, agents that disrupt actin cytoskeletal organization are found to upregulate endothelial cell Nitric Oxide Synthase activity. As a result, agents that disrupt actin cytoskeletal organization are useful in treating or preventing conditions that result from the abnormally low expression and/or activity of endothelial cell Nitric Oxide Synthase. Such conditions include pulmonary hypertension, ischemic stroke, impotence, heart failure, hypoxia-induced conditions, insulin deficiency, progressive renal disease, gastric or esophageal motility syndrome, etc. Subjects thought to benefit mostly from such treatments include nonhyperlipidemics and nonhypercholesterolemics, but not necessarily exclude hyperlipidemics and hypercholesterolemics.

  本发明提供了破坏肌动蛋白细胞骨架组织的制剂的用途。在本发明中，破坏肌动蛋白细胞骨架组织的制剂可上调内皮细胞一氧化氮合成酶的活性。因此，破坏肌动蛋白细胞骨架组织的制剂可用于治疗或预防因内皮细胞一氧化氮合成酶异常低表达和/或活性而导致的病症。这些病症包括肺动脉高压、缺血性中风、阳痿、心力衰竭、缺氧引起的病症、胰岛素缺乏、进行性肾病、胃或食管运动综合征等。被认为可从此类治疗中获益的对象主要包括非高脂血症患者和非高胆固醇患者，但不一定排除高脂血症患者和高胆固醇患者。
• Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
  申请人：——

  公开号：US20030013703A1

  公开（公告）日：2003-01-16

  A use for agents that disrupt actin cytoskeletal organization is provided. In the instant invention, agents that disrupt actin cytoskeletal organization are found to upregulate endothelial cell Nitric Oxide Synthase activity. As a result, agents that disrupt actin cytoskeletal organization are useful in treating or preventing conditions that result from the abnormally low expression and/or activity of endothelial cell Nitric Oxide Synthase. Such conditions include hypoxia-induced conditions. Subjects thought to benefit mostly from such treatments include nonhyperlipidemics and nonhypercholesterolemics, but not necessarily exclude hyperlipidemics and hypercholesterolemics.

  本发明提供了破坏肌动蛋白细胞骨架组织的制剂的用途。在本发明中，破坏肌动蛋白细胞骨架组织的制剂可上调内皮细胞一氧化氮合成酶的活性。因此，破坏肌动蛋白细胞骨架组织的制剂可用于治疗或预防因内皮细胞一氧化氮合成酶异常低表达和/或活性而导致的病症。这些病症包括缺氧引起的病症。被认为可从此类治疗中获益的对象主要包括非高脂血症患者和非高胆固醇患者，但不一定排除高脂血症患者和高胆固醇患者。
• XIDAKA, XIROESI;TANAKA, TOSIO;ITO, YASUO;KATO, XIDEHO;EHTTYU, EHJITI;OGAV+
  作者：XIDAKA, XIROESI、TANAKA, TOSIO、ITO, YASUO、KATO, XIDEHO、EHTTYU, EHJITI、OGAV+

  DOI：——

  日期：——